E-mail: Jaroslav.Cermak@uhkt.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A Distinct Expression of Various Gene Subsets in CD34+ Cells Obtained From Patients with Early and Advanced Myelodysplastic Syndrome
- A Lack of Correlation between EVI1 Expression, MDS Subtype and Karyotype Abnormalities Suggests Multiple Pathways Involved in EVI1 Impact on Hematopoietic Cells in MDS Patients.
- A Limited Impact of Chemotherapy on Prolonged Survival in Myelodysplasia (MDS). An Analysis of 142 Patients with Advanced Disease.
- A LONGITUDINAL OBSERVATIONAL STUDY ON THE HEALTH-RELATED QUALITY OF LIFE IN IPSS LOW-RISK MDS - IMPACT OF TIME COURSE AND TRANSFUSION NEED
- Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine
- Can Gene Methylation, Telomere Length and Activity of Telomerase Help with Individual Risk and Treatment Strategy of MDS Patients?
- CBFβ/MYH11 Hypomethylation Signature In Patients With Acute Myeloid Leukaemia
- CIRCULATING MICRORNAS IN PLASMA OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
- Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes
- COMBINATION CHEMOTHERAPY IN MDS: A LIMITED IMPACT ON SURVIVAL AS A SINGLE THERAPY, A BENEFICIAL EFFECT ON OUTCOME OF SUBSEQUENT TRANSPLANTATION
- Combination Chemotherapy Leading In Advanced MDS Patients to a Rapid Clearence of Bone Marrow Blasts Prior Stem Cell transplantation (SCT) Is Superior to up-Front SCT Even with Intensified Conditioning for Long-Term Survival
- COMBINED IMMUNOSUPPRESSIVE TREATMENT IN PATIENTS WITH EARLY MYELODYSPLASIA
- Comparison of DNA Methylation and Expression Status Prior Azacytidine Treatment and their Relationship to Overall Survival and Clinical Response of MDS Patients
- COMPLEX CHROMOSOMAL ABERRATIONS IN BONE MARROW CELLS OF 86 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
- COMPLEX CHROMOSOMAL REARRANGEMENTS IN ADULT PATIENTS WITH AML ARE INDEPENDENT PROGNOSTIC FACTOR
- Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial
- DEFERASIROX REPRESENTS AN EFFECTIVE ORAL IRON CHELATOR IN LOW OR INTERMEDIATE-1 RISK PATIENTS WITH MDS – A COMPARATIVE STUDY TO THE TREATMENT WITH DEFERIPRONE
- DETECTION OF STRUCTURAL ABERRATIONS OF CHROMOSOME 7 IN MYELOID MALIGNANCIES USING COMBINATION OF MOLECULAR CYTOGENETIC TECHNIQUES
- Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry
- DNA METHYLATION PROFILING IN PATIENTS WITH MYELODYSPLASTIC SYNDROME TREATED WITH 5-AZACYTIDINE
- DYNAMICS OF TELOMERE LENGTH, THE STATUS OF CDKN2B GENE METHYLATION AND TELOMERASE ACTIVITY AS A POTENTIAL UNSPECIFIC PROGNOSTIC MARKERS IN MDS
- Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry
- EFFECT OF LENALIDOMIDE TREATMENT ON THE EXPRESSION OF FLI1, EKLF, TP53, HDM2, PU. 1 AND IL-6 GENES IN 5Q- SYNDROME
- EFFICIENCY AND SAFETY OF ADMINISTRATION OF ORAL IRON CHELATOR DEFERIPRONE IN PATIENTS WITH EARLY MYELODYSPLASTIC SYNDROME (MDS)
- EUROPEAN PATTERN AND IMPACT OF THE USE ERYTHROPOIETIC AGENTS (ESAS)IN LOW AND INT-1 RISK MDS WITH PROPENSITY SCORING TECHNIQUES IN OBSERVATIONAL LONGITUDINAL STUDIES
- European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients
- EXPRESSION OF WT-1 IN HUMAN ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
- EXPRESSION PATTERNS OF CELL CYCLE AND DNA REPLICATION GENES DISCRIMINATE EARLY AND ADVANCED MDS
- EXPRESSION SIGNATURE OF GENES ASSOCIATED WITH TELOMERE-TELOMERASE COMPLEX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE LEUKEMIA: TEP1 GENE IS SURPRISINGLY UPREGULATED IN PROGRESSION OF MDS AND IN LEUKEMIC CELLS
- Fli-1 and EKLF Gene Expression in Patients with MDS 5q- Syndrome
- Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q)
- Gene Expression Changes In Patients with 5q- Syndrome Treated with Lenalidomide
- Gene Expression Profiles of CD34+ Cells in Myelodysplastic Syndrome
- Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry
- Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry
- High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide
- HIGH LEVELS OF CEREBLON MESSENGER RNA ARE THE CHARACTERISTIC FEATURE OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH 5Q DELETION AND ARE CONNECTED WITH THE EFFICACY OF LENALIDOMIDE
- CHROMOSOME 3 ABERRATIONS IN MYELOID MALIGNANCIES REVEALED BY MOLECULAR CYTOGENETIC TECHNIQUES AND THEIR PROGNOSTIC SIGNIFICANCE
- CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES
- IMMUNOLOGICAL BACKGROUND OF MDS, AN IMPACT ON PROGNOSIS AND PATHOGENESIS OF MDS
- IMPACT OF MDS ON HEALTH-RELATED QUALITY OF LIFE: A COMPARISON OF IPSS LOW-AND INT-1 RISK MDS PATIENTS FROM THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY AND EUROPEAN REFERENCE POPULATIONS
- Incidence a prognostický význam chromozomových změn u myelodysplastického syndromu
- INCIDENCE OF INVASIVE ASPERGILLOSIS (IA) IN A TERTIARY HEMATOLOGICAL CENTRE IN CZECH REPUBLIC, EVALUATION OF THE GALACTOMANNAN MONITORING
- Isolated Granulocytopenia in Patients with Unclassifiable MDS May Be Related to a Mutation of PIG-A Gene Leading to GPI-APs Deficiency Expressed Predominantly on Granulocytes
- Komplexní změny karyotypu u pacientů s mnohočetným myelomem (MM)
- Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry
- METHYLATION CHANGES IN CDKN2B AND CDKN2A GENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
- MICRORNA SIGNATURE OF CD34 CELLS IN MYELODYSPLASTIC SYNDROME PATIENTS WITH DEL(5Q)
- Modification of WPSS for the Time of Diagnosis Retains Its Prognostic Impact and Confirms Transfusion Dependency as An Important Parameter Affecting Survival in Early MDS Patients with Isolated Erythroid Dysplasia
- Molecular Cytogenetic Studies of Complex Karyotypes in Myelodysplastic Syndromes (MDS): Conventional Cytogenetics, FISH and Multiplex FISH (mFISH/mBAND)
- MOLECULAR CHARACTERIZATION OF BETA-THALASSEMIA AND HEMOGLOBIN VARIANTS IN THE CZECH AND SLOVAK POPULATIONS: AN UPDATE
- MONITORING OF ABERRANTLY METHYLATED GENES IN AML PATIENTS
- N-RAS GENE MUTATIONS ARE INDICATIVE OF AN UNFAVORABLE OVERALL SURVIVAL PROGNOSIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES, BUT NOT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
- New Mutation in ALAS2 as the Cause of X-Linked Sideroblastic Anemia Responsive to Pyridoxine: Comparison of ALAS2-Defective and DMT1-Defective BFU-E Growth
- Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients
- OXIDATIVE STRESS IN BLOOD PLASMA OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
- PERFORMANCE CHARACTERISTICS OF CONSENSUAL APPROACHES FOR SMALL AND MINOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE DETERMINATION BY FLOW CYTOMETRY
- Post hoc analysis of relationship between baseline white blood cell count and survival outcome in a randomized phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
- Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes
- Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry
- Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry
- Prognostický význam podávání transfuzí erytrocytů nemocným s časnými formami myelodysplastického syndromu
- Putative Monosomy 5 In Myelodysplastic Syndromes (MDS) Is Probably Resulting From Chromothripsis
- Radikální onkochirurgické výkony u nemocných ve vysokém věku
- Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML.
- RESULTS OF CLONALITY ASSAY AND MEASUREMENT OF APOPTOTIC RATE AND TELOMERE LENGTH SUPPORT USEFULNESS OF SEPARATION OF REFRACTORY CYTOPENIA FROM REFRACTORY ANEMIA AS A DISTINCT SUBTYPE OF EARLY MDS
- SERIOUS EBV ENCEPHALITIS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) – SERIES OF 3
- SURVEY-BASED HEMATOLOGIST VIEW OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN OPPORTUNITY FOR IMPROVEMENT OF DIAGNOSIS AND MANAGEMENT
- Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q)
- TELOMERASE ACTIVITY INCREASES IN PROGRESSION OF MYELODYSPLASTIC SYNDROMES AND IS COMMON FEATURE OF UNTREATED ACUTE MYELOID LEUKEMIA ASSOCIATED WITH A PORTION OF BLASTS IN ANALYZED TISSUE
- The Population-Based "real world" of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients
- The Prognostic Significance of TP53
- THE ROLE OF TP53 MUTATIONS IN LOW-RISK MDS PATIENTS
- The Significance of Megakaryocytic Transcription Factor Fli1 and Erythroid Transcription Factor EKLF in the Ribosomopathies: 5q Minus Syndrome and Diamond-Blackfan Anemia. the Role of Fli1 in p53 Regulation and in 5q Minus Syndrome Megakaryopoiesis
- THE SIGNIFICANT ASSOCIATION BETWEEN PRIMARY MYELODYSPLASTIC SYNDROME AND SINGLE NUCLEOTIDE POLYMORPHISMS
- Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age
- Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry
- TRUE MONOSOMY OF CHROMOSOME 5 IS PRESUMABLY NOT AN ISOLATED CYTOGENETIC ENTITY IN MDS
- TWO YEARS WITH PANDEMIC H1N1 2009 INFLUENZA A IN A TERTIARY HEMATOLOGY DEPARTMENT
- UP-REGULATION OF SUBSET OF MIRNAS LOCATED IN 14Q32 DOMAIN IN CD34 BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME
- Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry
- VARIATION OF TELOMERE-TELOMERASE COMPLEX COMPONENTS IN MYELODYSPLASTIC SYNDROMES: TELOMERE LENGTH AND EXPRESSION OF THE HTERT GENE SEEM TO BE THE MOST VALUABLE FOR DISEASE PROGNOSIS
Články v Klinické onkologii
- Difúzní B – velkobuněčný lymfom projevující se jako autoimunní hemolytická anemie. Diagnostická úskalí
- Model populačního klinického registru umožň ujícího hodnocení léčebné péče: projekt ALERT (akutní leukemie-klinický registr)
- Myelodysplastický syndrom, MKN klasifikace a Národní onkologický registr ČR
- Naše výsledky kombinované systémové a intraarteriální chemoterapie jaterních metastáz kolorektálního karcinomu a karcinomu žlučových cest
- Návrh populační registrace hematoonkologických diagnóz vycházející z WHO klasifikace nádorových chorob z roku 1999, z hodnocení základních léčebných přístupů a z požadavků Národního onkologického registru ČR
- Odchylky v krevním obraze a poruchy hemostázy u pacientů se solidními tumory – přehled a popis případů
- Předoperační imunomodulační léčba u nemocných s kolorektálním karcinomem - výsledky randomizované studie
- Stanovisko odborných společností k indikaci a použití antimykotik se systémovým účinkem
